A Phase 2 randomized, double-blind, placebo-controlled, multicenter study of the efficacy and safety of AL002 in patients with prodromal to mild Alzheimers disease
Study of AL002 for Patients with Early Alzheimers Disease
Sponsor: Alector Inc.
Enrolling: Male and Female Patients
IRB Number: AAAT2514
U.S. Govt. ID: NCT04592874
Contact: Katrina Cuasay: 212-305-2077 / kc2305@cumc.columbia.edu
Additional Study Information: This is a phase 2 study evaluating a new drug, AL002, in persons with early Alzheimer's Disease. Participants will be randomized to receive either AL002 or placebo, intravenously every four weeks, for a total period of about two years. The purpose is to evaluate the efficacy and safety of this drug, and this study involves pen and paper testing, and MRI and PET scans.
This study is closed
Lawrence Honig, MD, PhD
Do You Qualify?
Are you between the ages of 50-85? Yes No
Have you been diagnosed with Alzheimers disease? Yes No
Do you have an available study partner? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Katrina Cuasay